Royalty Report: Drugs, Disease, Biotechnology – Collection: 29256

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Biotechnology
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29256

License Grant
As a result of a merger, the Licensee received the exclusive worldwide License to DR Cysteamine, a proprietary enterically coated formulation of cysteamine bitartrate, a cystine depleting agent currently approved by the FDA for nephropathic cystinosis. Cysteamine bitartrate is prescribed for the management of the genetic disorder known as cystinosis, is sold as a non-enterically coated capsule as CystagonTM by Mylan Laboratories.
License Property
DR Cysteamine is a proprietary enterically coated formulation of cysteamine bitartrate, a cystine depleting agent currently approved by the FDA for nephropathic cystinosis.
Field of Use
Cysteamine bitartrate is prescribed for the management of the genetic disorder known as cystinosis, is sold as a non-enterically coated capsule as CystagonTM by Mylan Laboratories. Cystinosis is a lysosomal storage disease characterized by the abnormal accumulation of the amino acid cystine.

IPSCIO Record ID: 203546

License Grant
University grants a license under Patent Rights to make and have made, to use and have used, to sell and have sold, to offer for sale, and to import and have imported Licensed Products and to practice Licensed Methods and to use Technology, in the Field within the Territory and during the Term.  The license granted herein is exclusive for Patent Rights and non-exclusive for Technology.
License Property
The patent is for Enterically Coated Cysteamine, Cystamine and Derivatives Thereof.
Field of Use
The Field means human therapeutics for metabolic and neurologic disorders.

IPSCIO Record ID: 3433

License Grant
As a result of a merger, the Licensee obtained exclusive, worldwide rights to a delayed-release cysteamine bitartrate (DR Cysteamine) currently in a Phase II clinical trial for treatment for patients with Huntington’s Disease from the University.  Previous research has indicated that DR Cysteamine can prevent abnormal neuronal cell death caused by Huntington’s.  Preclinical studies demonstrated in 2006 prevention of neuronal apoptosis through usage of cysteamine. Treatment with cysteamine is linked to increased levels of Brain derived neurotrophic factor (BDNF) which protects brain cells and promotes growth of new brain cells. Their study showed an increase in both brain and blood levels of BDNF, which allows this protein to be used as a biomarker.
Field of Use
The rights granted apply to the healthcare industry.  BDNF is known to be depressed in patients with Huntington’s.  If proven efficacious and viable, treatment with DR Cysteamine could protect from the neuronal cell death by increasing levels of protective BDNF.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.